^
Association details:
| Biomarker: | EGFR amplification |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis
Excerpt:
It shows high EFGR GCN had benefit effect on OS when treated with cetuximab or panitumumab in mCRC patients...In MoAbs subgroup, increased EGFR GCN was statistically significantly associated with increased ORR in studies of cetuximab treated patients (HR=6.296; 95% CI: 3.990-9.935) and panitumumab treated patients (HR=34.517; 95% CI: 1.826-652.370).
DOI:
10.3978/j.issn.1000-9604.2014.01.10
Source:
Title:
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
Excerpt:
Eight of nine of patients with objective responses who were assessable by fluorescence in-situ hybridisation (FISH) had an increased EGFR copy number. By contrast, one of 21 non-responders assessable by FISH had an increased EGFR copy number (p<0.0001 for responders vs non-responders, Fisher's exact test).
DOI:
10.1016/S1470-2045(05)70102-9
Source:
Title:
EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis
Excerpt:
We retrospectively collected tumors from 173 patients with mCRC. All but one patient received a cetuximab-based regimen as second-line or greater therapy...In patients with KRAS wild-type tumors (n = 116), BRAF mutations (n = 5) were weakly associated with lack of response (P = .063) but were strongly associated with shorter progression-free survival (P < .001) and shorter overall survival (OS; P < .001).
DOI:
10.1200/JCO.2008.21.6796
Source:
Title:
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
Excerpt:
An increased EGFR copy number was found in 3 patients (10%) and was significantly associated with an objective tumor response to cetuximab (P = 0.04).
DOI:
10.1158/0008-5472.CAN-06-0191
Source:
Title:
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study
Excerpt:
FISH analysis of 87 metastatic colorectal cancer patients treated with cetuximab was done...In multivariable analysis, EGFR GCN testing provided significant information independent of the KRAS status to predict response (P = 0.016) and overall survival (P = 0.005).
DOI:
10.1158/1078-0432.CCR-08-0449
